While controversy exists over whether PD-L1 expression levels can serve as a biomarker for ICI-treated HCC, it is important to note that previous clinical trials have been conducted across various nations and institutions, resulting in inconsistent procedures for detecting PD-L1. The gene discussed is CD274; the disease is hepatocellular carcinoma.